Back

Real-world efficacy and tolerability of lipid-lowering therapy in children with monogenic familial hypercholesterolemia in primary care

28 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Lipid lowering (1) Drug therapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Raphael Siegfried Schmieder

German Heart Center Muenchen Technical University of Munich, Munich (Germany)

6 More presentations in this session

Presentation thumbnail
Bridging the gap: real-world eligibility for lipoprotein(a)-targeted therapies in chronic and acute coronary syndrome
Doctor E. Steinacher (Vienna, AT)
Abstract Slides
Presentation thumbnail
LDL-C target achievement does not equal risk resolution after ACS: residual atherogenic and inflammatory burden despite maximal oral triple lipid therapy
Doctor K. Mahajan (Mandi, IN)
Abstract Slides
Presentation thumbnail
Association of LDL-C/ApoB ratio with pathogenic variants in familial hypercholesterolemia
Doctor F. Wollmann (Wien, AT)
Abstract Slides
Presentation thumbnail
Association of apolipoprotein B and lipoprotein(a) with severe atherosclerotic cardiovascular disease in patients with acute coronary syndrome: the modifying effect of prior lipid-lowering therapy.
Mr A. Meseguer Hernandez (Cartagena, ES)
Abstract Slides
Presentation thumbnail
Elective coronary revascularisation represents an unutilised opportunity to optimise lipid management: results from a multicentre observational cohort
Miss M. van den Bogaart (Amsterdam, NL)
Abstract Slides

Access the full session

Session thumbnail
Lipid lowering (1)

The Event

Event poster

ESC Congress 2026

28 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Effectiveness of PCSK9 inhibitors in homozygous familial hypercholesterolemia: insights from a Saudi Arabia genetic population
3 April 2025
thumbnail
Congress Presentation
A collaborative working project in primary care: optimising lipid lowering therapies for secondary prevention in high risk patients
4 April 2025
thumbnail
Congress Presentation
Lipoprotein(a) levels in children with suspected familial hypercholesterolaemia identified through universal lipid screening: association with pathogenic variants
31 August 2025
thumbnail
Congress Presentation
Real-world use of rosuvastatin 40 mg and ezetimibe 10 mg after ACS: is this combination effective in achieving guideline-recommended LDL-C goals after discharge?
20 March 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources